

Electronic Acknowledgement Receipt

EFS ID:	8229149
Application Number:	10568367
International Application Number:	
Confirmation Number:	2344
Title of Invention:	2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
First Named Inventor/Applicant Name:	Carlos Garcia-Echeverria
Customer Number:	75074
Filer:	Arlene Kay Musser/Ryan T. Dee
Filer Authorized By:	Arlene Kay Musser
Attorney Docket Number:	32910B-US-PCT
Receipt Date:	16-AUG-2010
Filing Date:	18-AUG-2006
Time Stamp:	18:11:07
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1440
RAM confirmation Number	6819
Deposit Account	504409
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	PAT032910B-US-PCT_RCE_SB30EFS.pdf	37783 <small>7ff6da77ce031e4869f4dce44ba35e7637cd0813</small>	no	3
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		PAT032910B-US-PCT_Response_to_Final_OA_mailed_16Mar2010.pdf	57951 <small>8acc6073-7937603128a0a7e9d01c6e68d4c220</small>	yes	7
Multipart Description/PDF files in .zip description					
Document Description		Start	End		
Amendment After Final		1	1		
Claims		2	5		
Applicant Arguments/Remarks Made in an Amendment		6	7		
Warnings:					
Information:					
3	Terminal Disclaimer Filed	PAT032910B-US-PCT_Terminal_Disclaimer_filed_16Aug10.pdf	64704 <small>03134f50a49c7239f8f85488b9687c37ab0b2854</small>	no	2
Warnings:					
Information:					
4	Fee Worksheet (PTO-875)	fee-info.pdf	33988 <small>b5d26adcc6c4fd7b354edc237552860c9087</small>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			194426		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.